Shares of AstraZeneca plc (ADR) (NYSE:AZN) ended Thursday session in red amid volatile trading. The shares closed down -0.14 points or -0.42% at $33.04 with 6.07 million shares getting traded. Post opening the session at $32.83, the shares hit an intraday low of $32.82 and an intraday high of $33.08 and the price vacillated in this range throughout the day. The company has a market cap of $82.77 billion and the numbers of outstanding shares have been calculated to be 1.26 billion shares.
AstraZeneca plc (ADR) (AZN) on September 1, 2016 announced results from the SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol LABA (long-acting beta2-adrenergic agonist) safety study showing patients with controlled and uncontrolled asthma had a comparable risk of serious asthma-related events and a lower risk of asthma exacerbations when formoterol was combined with budesonide versus budesonide alone.
The study compared the safety of formoterol, a LABA, used in combination with budesonide, an inhaled corticosteroid (ICS)–the two active therapies in SYMBICORT pressurized metered dose inhaler (pMDI)–against budesonide (pMDI) to evaluate the risk of serious asthma-related events. These events are defined as a composite endpoint of asthma related events including asthma-related deaths, intubations, and hospitalizations, with time to first serious asthma-related event as the primary endpoint.
The results showed a comparable risk of serious asthma-related events when formoterol was combined with budesonide versus budesonide alone. Based on a predefined non-inferiority margin, the upper limit of the 95% confidence interval (CI) for the hazard ratio (HR) of the primary safety endpoint needed to be less than two. As a result, the findings demonstrated statistical non-inferiority of SYMBICORT to budesonide for time to first serious asthma-related event (HR [1.073], 95% CI, [0.698-1.650]). Furthermore, SYMBICORT therapy resulted in a 16.5% lower risk of asthma exacerbations than budesonide (HR, 0.835; 95% CI, 0.745 to 0.937; P = 0.002).
Shares of Medtronic PLC (NYSE:MDT) ended Thursday session in green amid volatile trading. The shares closed up +0.11 points or 0.13% at $86.26 with 4.19 million shares getting traded. Post opening the session at $85.77, the shares hit an intraday low of $85.77 and an intraday high of $86.63 and the price vacillated in this range throughout the day. The company has a market cap of $120.21 billion and the numbers of outstanding shares have been calculated to be 1.38 billion shares.
Medtronic PLC (MDT) on September 8, 2016 recognized as one of the world`s leading companies for sustainability with its ranking on the Dow Jones Sustainability North America Index (DJSI North America) for the ninth consecutive year. DJSI North America analyzes companies on a variety of sustainability criteria, including economic performance, environmental stewardship and social responsibility. This adds to the recognition Medtronic received earlier this year through its continued inclusion in the FTSE4Good Index Series.
Medtronic is committed to advancing sustainability by strategically focusing on issues identified as most material to long-term success, including access to healthcare, product quality and patient safety, ethical business practices, responsible supply management, employee engagement and development, human rights, and environmental stewardship.
“We are honored to once again be recognized as a global leader in environmental, social, and corporate governance (ESG) initiatives. Strong and sustainable ESG practices and our efforts to address chronic disease are important drivers of delivering long-term consistent growth for all of our stakeholders,” said Omar Ishrak, Medtronic chairman and CEO. “We are pleased to be recognized for these efforts by our inclusion on the DJSI North America Index.”